GEMSTONE-301 is a phase III randomized, double-blind, study to explore the efficacy and safety of CS1001 compared with a placebo as consolidation therapy for stage III unresectable NSCLC patients.

GEMSTONE-301: A Randomized, Double-blind, Placebo-controlled, Phase 3 Study of Sugemalimab in Patients With Unresectable Stage III Non-Small Cell Lung Cancer Without Progression After …

Jun 15, 2023 · Sugemalimab versus placebo after concurrent or sequential chemoradiotherapy in patients with locally advanced, unresectable, stage III non-small-cell lung cancer in China …

To our knowledge, GEMSTONE-301 was the first phase 3 trial to address the efficacy of sequential chemoradiotherapy and consolidation immunotherapy in patients with good performance status …

Jun 6, 2022 · The NMPA approval is based on the GEMSTONE-301 study, a multicenter, randomized, double-blind phase 3 clinical trial, designed to evaluate the efficacy and safety of sugemalimab as a...

Aug 11, 2022 · “The results of the GEMSTONE-301 study suggest that sugemalimab could be safely and effectively used after concurrent or sequential chemoradiotherapy and should be a new standard …

We assessed the efficacy and safety of sugemalimab, an anti-PD-L1 antibody, in patients with stage III NSCLC whose disease had not progressed after concurrent or sequential chemoradiotherapy.

28p) monoclonal antibody (mAb) developed by the OMT transgenic rat platform. The Phase Ia/Ib study (GEMSTONE-101, NCT03312842) demonstrated that CS1001 was well tolerated and had promisi g …

Jan 14, 2022 · GEMSTONE-302 aimed to evaluate the efficacy and safety of a PD-L1 inhibitor, sugemalimab, plus chemotherapy for patients with metastatic squamous or non-squamous NSCLC. …

Gemstone-301: A Phase III Clinical Trial of CS1001 As Consolidation Therapy in Subjects with Locally Advanced/Unresectable (Stage III) Non-Small Cell Lung Cancer (NSCLC) Who Have Not …